Semi-annual Report for 2026
Filed with SSE · · 195 pages · Chinese
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huahai Pharmaceutical
- Announcement on Subsidiary Passing the Drug GMP Compliance Inspection
- Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
- Announcement on the Signing of the Four-Party Supervision Agreement for Raised Funds
- Announcement on Obtaining Approval for Drug Clinical Trials by Subsidiary
- Announcement on Appointment of Senior Management
Later from Zhejiang Huahai Pharmaceutical
- Announcement on Pledge of Certain Shares Held by the Shareholder
- Announcement on Obtaining Overseas Marketing Authorization for the Formulation Products
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- First Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"
- Second Indicative Announcement on Maturity Redemption and Delisting of "HUAHAI Convertible Bonds"
Follow Zhejiang Huahai Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huahai Pharmaceutical